id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2204-0003,FDA,FDA-2020-E-2204,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-12-14T05:00:00Z,2020,12,2020-12-14T05:00:00Z,,2020-12-14T20:13:06Z,,0,0,090000648499d78a
FDA-2020-E-2204-0001,FDA,FDA-2020-E-2204,Letter from US Patent and Trademark Office,Other,Letter(s),2020-11-16T05:00:00Z,2020,11,2020-11-16T05:00:00Z,,2020-11-16T21:15:09Z,,0,0,0900006484962542
FDA-2020-E-2204-0002,FDA,FDA-2020-E-2204,"Patent Term Extension Application from Ultragenyx  Pharmaceutical, Inc.",Other,Application,2020-11-16T05:00:00Z,2020,11,2020-11-16T05:00:00Z,,2020-11-16T21:17:42Z,,0,0,0900006484962543